OMS 527

Drug Profile

OMS 527

Alternative Names: OMS527; PDE7 inhibitor - Omeros; Type 7 cyclic nucleotide phosphodiesterase inhibitor - Omeros

Latest Information Update: 19 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma
  • Developer National Institute on Drug Abuse; Omeros Corporation; The Parkinsons Institute and Clinical Center
  • Class Antiparkinsonians; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Type 7 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug abuse
  • Preclinical Impulse control disorders; Movement disorders

Most Recent Events

  • 17 Jul 2018 Phase-I clinical trials in Drug abuse (In volunteers) in USA (unspecified route)
  • 27 Jun 2018 Omeros Corporation plans a phase I trial for OMS 527 in Drug abuse (In volunteers) in July 2018
  • 27 Jun 2018 US FDA approves IND application for OMS 527 in Drug abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top